The cardiovascular case for GLP-1 receptor agonists has rested almost entirely on people who already had heart disease. What happens when the same drug-driven risk factor shifts are applied to adults who haven't yet had a cardiac event — the much larger primary prevention population? That question has enormous public health stakes, and a new modeling study from the Journal of the American College of Cardiology attempts to answer it rigorously.
Using a cohort of 610,789 cardiovascular-disease-free adults drawn from the Global Cardiovascular Risk Consortium — spanning European and North American populations — investigators built a predictive model linking five key biomarkers to 10-year CVD incidence and all-cause mortality. The biomarkers were BMI, glycosylated hemoglobin, systolic blood pressure, high-sensitivity C-reactive protein, and non-HDL cholesterol. They then applied sex-stratified, placebo-adjusted changes in those same biomarkers observed in the SELECT semaglutide trial to 200,012 individuals from two contemporary health examination surveys. The primary target group — roughly 21,720 individuals with BMI ≥27 kg/m² and a baseline SCORE2 cardiovascular risk ≥7.5% — showed meaningful projected reductions in 10-year CVD risk on the order of 20%, driven by simultaneous favorable shifts across all five risk factors rather than any single pathway.
This emulation design is methodologically clever but carries important caveats. The approach inherits assumptions from the SELECT trial's effect sizes, which were measured in individuals with established CVD — a meaningfully different physiological context than primary prevention. Translating those risk factor changes to a healthier population may overestimate benefit if the mechanisms of cardiovascular protection in GLP-1RA therapy are partly independent of the five modeled biomarkers, such as through direct cardiac or vascular effects. The analysis is also observational-emulation rather than randomized, so confounding cannot be ruled out. Still, the scale of the underlying dataset lends credibility that smaller modeling exercises lack. For health-conscious adults in the elevated-risk category, this represents incremental but genuinely relevant evidence that GLP-1 therapy's cardiovascular upside may extend well beyond secondary prevention.